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Abstract
Objective: This study compared the efficacy, safety, device satisfaction, and quality of life (QOL) in people with
diabetes using an insulin bolus-patch versus current devices (pen/syringe) to deliver mealtime insulin.
Research Design and Methods: Thirty-eight subjects with diabetes (26 with type 1 and 12 with type 2) were
randomized to bolus-patch or current injection device (55% pen and 45% syringe) to deliver mealtime insulin in
a multicenter, 6-week crossover study. Efficacy was assessed by equivalence in mean daily seven-point blood
glucose (MDBG). Safety assessments included severe hypoglycemia episodes, adverse device effects (ADEs),
and adverse events (AEs). Device satisfaction was determined by the validated Insulin Delivery System Rating
Questionnaire (IDSRQ) and QOL by the validated Diabetes Specific QOL Scale (DSQOLS).
Results: Using bolus-patch, MDBG (mean – SE) was equivalent to that using pen/syringe (8.61 – 0.28 vs.
9.02 – 0.26mmol/L; P = 0.098). SD of the seven-point blood glucose measurements was lower using bolus-patch
(3.18 – 0.18 vs. 3.63 – 0.17 mmol/L; P = 0.004), as was the coefficient of variation (CV) (37.2 – 1.7 vs. 40.3 – 1.7%;
P = 0.046). Hemoglobin A1c, 1,5-anhydroglucitol, fructosamine, and insulin use were similar between groups.
There were no severe hypoglycemia episodes or serious ADEs. Between-device AEs were comparable. Subjects
scored better on six of seven subscales on the DSQOLS and five of six subscales on the IDSRQ while using bolus-
patch versus pen/syringe. At study completion, 76% of subjects would choose to switch to bolus-patch
(P = 0.001).
Conclusions: Delivery of mealtime insulin with bolus-patch compared with pen/syringe resulted in equivalent
MDBG, lower SD and CV of seven-point blood glucose measurements, good safety, significant device satis-
faction, and improved QOL.
Introduction
Although insulin therapy can improve glycemic con-trol, only 49.8% of people with diabetes in the United
States have acceptable glycemic control as defined by gly-
cated hemoglobin (HbA1c) of < 7.0%.1,2 This is partly due to
insulin usage barriers that impede the patient’s ability to
adopt and adhere to basal plus bolus dosing regimens.3,4
These barriers include difficulty of insulin administration,
difficulty of multiple dosing, relative complexities of delivery
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devices, situational availability of delivery devices and insu-
lin, discreetness of delivery, fear of injection, and costs.5–7 In a
study of 502U.S. adults with type 1 or 2 diabetes injecting
insulin, 57% self-reported regular intentional omission of in-
sulin, with 20% omitting insulin injections regularly.8 Missed
bolus doses per week have been shown to correlate signifi-
cantly with HbA1c (r= 0.6) (P < 0.0001) with a 0.92% increase
in HbA1c for every four meal boluses missed per week.9
The aim of this feasibility study was to compare efficacy,
device satisfaction, and quality of life (QOL) in people with
type 1 or 2 diabetes delivering mealtime insulin using a novel
insulin bolus-patch (Finesse, Calibra Medical, Inc., Red-
wood City, CA) versus current devices that deliver bolus in-
sulin (pen/syringe). The insulin bolus-patch (henceforth
referred to as bolus-patch) is classified as a new Food and
Drug Administration product code, OPP, under 21 CFR
880.5725.
A preliminary report of the results of this study has been
published in abstract form at the Tenth Annual Diabetes
Technology Meeting, November 11–13, 2010, held in Bethes-
da, MD.10
Research Design and Methods
The primary end point was to test the hypothesis that de-
livering mealtime insulin (HumalogU 100 [Eli Lilly and Co.,
Indianapolis, IN] or NovoLog U 100 [Novo Nordisk Phar-
maceuticals Inc., Princeton, NJ]) using bolus-patch results in
equivalent mean daily (seven-point) blood glucose (MDBG)
as injecting the same insulin with current pen/syringe. All
subjects injected their basal insulin using their current pen/
syringe. A secondary end point was to test for superiority of
MDBG once equivalence was established. Daily glucose pro-
files (average of three non-consecutive-day measures) were
obtained using seven-point self-monitoring of blood glucose
(SMBG), which included a preprandial (for each meal), 2-h
postprandial (for each meal), and bedtime measurement. The
SMBG was used to calculate glycemic variability indices SD,
coefficient of variation (CV), M-value,11 and mean amplitude
of glycemic excursion (MAGE).12 Additional secondary end
points included HbA1c, 1,5-anhydroglucitol, fructosamine,
and safety parameters including severe hypoglycemia epi-
sodes as defined by the Diabetes Control and Complication
Trial,13 adverse events (AEs), and adverse device effects
(ADEs). Device satisfaction for insulin delivery andQOLwere
also secondary end points.
The design was a randomized, open-label, crossover study
in five centers with a 1-week run-in period followed by a 12-
week treatment period with clinic visits at baseline, 6-week
crossover, and the study end at 12 weeks. Subjects conducted
standardized SMBG testing during the run-in period on their
current pen/syringe and then were randomized to use either
bolus-patch for mealtime insulin delivery for 6 weeks or to
continue with pen/syringe (pens provided) during Phase 1.
After Phase 1, subjects crossed over to the alternate treatment
for Phase 2. This design was chosen to gain comparative de-
vice data while eliminating potential confounding effects of
time. Subject allocation to treatment order by site and type of
diabetes was centralized and conducted by a remote online
system to guard against potential selection bias (Simplified
Clinical Data Systems, LLC, Milford, NH). Subjects were al-
lowed to adjust their insulin depending on their blood glucose
during the study as they would have prior to entering the
study as prescribed by their physicians. Subjects gave written
informed consent approved by local Institutional Review
Boards. The study was conducted in accordance with the
principles of the Declaration of Helsinki and of Good Clinical
Practice.
Subjects
Adults with type 1 or 2 diabetes using a stable basal plus
bolus insulin regimen (four or more injections per day) for at
least 3 months were eligible for this study. Other inclusion
criteria were 18–75 years of age, HbA1c 7.0–9.5%, stable oral
medication for 3 months, and bodymass index of £ 32 kg/m2.
Exclusion criteria were unstable cardiac disease (medical
history), abnormal hepatic (alanine or aspartate aminotrans-
ferase levels ‡ 2.5 times the upper limit) or renal (creatinine
> 265.2lmol/L) function, evidence of gastroparesis (treat-
ment with medication), current use of NPH insulin, regular
insulin, pramlintide (Symlin, Amylin Pharmaceuticals, San
Diego, CA), or exenatide (Byetta, Amylin Pharmaceuticals),
use of continuous subcutaneous insulin infusion within the
preceding 3 months, women who were pregnant or breast
feeding, one or more severe hypoglycemia episodes as de-
fined by theDiabetes Control andComplications Trial13 during
the preceding 6 months, and hypoglycemia unawareness
(medical history).
Study treatments
The bolus-patch is small (65 · 35 · 8mm) (Fig. 1A) and
wearable for up to 3 days (Fig. 1B) and allows manual de-
livery of bolus insulin subcutaneously through a soft cannula.
The bolus-patch is discreet for use in social situations (insulin
can be dosed through clothing) without a portable digital
accessory (Fig. 1C). The bolus-patch holds 200 units of insulin,
administered in 1- or 2-unit increments by actuating the but-
tons (Fig. 1D). The bolus-patch requires 15–20min of self-
training or training by a healthcare provider.
Subjects were instructed to perform SMBG daily per stan-
dard of care, to record insulin doses and SMBG (seven-point)
for three non-consecutive days during run-in and the last
week of Phases 1 and 2, and to record AEs, ADEs, and severe
hypoglycemia episodes. Study supplies were provided and
included glucose meters and consumables (lancets and test
strips), insulin pens and consumables (needles), and vials of
rapid-acting insulin. Healthcare providers completed inser-
tion site reaction assessments for all devices.
Analytical measurements
Daily glucose was measured using a memory glucose
meter (OneTouch Ultra2, Lifescan, Inc., Milpitas, CA) and
was evaluated for non-severe biochemical hypoglycemia
(glucose < 3.89mmol/L) and non-severe biochemical hyper-
glycemia (glucose > 10mmol/L). Laboratory tests (fasting
plasma glucose, HbA1c, 1,5-anhydroglucitol, and fructosa-
mine) were done by a central laboratory (Quest Diagnostics,
Cincinnati, OH) at the end of phases 1 and 2. Subject satis-
faction with insulin delivery was assessed by self-report on
the validated Insulin Delivery System Rating Questionnaire
(IDSRQ)14 and QOL by the validated Diabetes Specific QOL
Scale (DSQOLS).15
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Statistical methods
Pre-study power calculations using PASS version 2005
(Number Cruncher Statistical Systems, Kaysville, UT) deter-
mined that 28 completed subjects provided 90% power to de-
tect equivalence (i.e., non-inferiority) for the primary end point
of MDBG of bolus-patch compared with pen/syringe using a
two-sided a level of 0.05, when the margin of equivalence for
MDBG is 1.11mmol/L, the true mean difference is 0.0, and the
SD of the differences is 1.72mmol/L. Equivalence will be es-
tablished if the upper bound of the 95% confidence interval of
the treatment difference for MDBG is below 1.11mmol/L. For
evaluating the subgroup of subjects with type 1 diabetes, 20
completed subjects would provide 78% power to detect
equivalence for MDBG. A 2· 2 crossover design with an equal
number in each sequence was used for this estimate.
A secondary end point was to test for superiority of MDBG
once equivalence was established. This was conducted at a
two-sided a level of 0.05, and confidence intervals were calcu-
lated at 95%, two-sided. A two-period, two-treatment cross-
over analysis of variance model was used to compare devices
for continuous measures. A subgroup analysis using the same
crossover model was performed examining the interaction of
treatment with the subgroups of diabetes type, injection device
(pen vs. syringe), gender, and age (< 65 vs. ‡ 65 years). For
categorical measures, summary statistics including sample
size, frequency, and percentages were performed by treatment.
McNemar’s test for paired responses was used for device
comparisons. All analyses were implemented using SAS ver-
sion 8.2 or higher (SAS Institute Inc., Cary, NC).
Results
Study population
Of 56 people screened for the study, 38 subjects with dia-
betes (26 with type 1 and 12 with type 2) were randomized to
one of two sequence groups: bolus-patch followed by pen/
syringe (19 patients) or pen/syringe followed by bolus-patch
(19 patients). The 18 screen failures included 15 who did not
meet the inclusion criteria for HbA1c, two who withdrew
consent prior to randomization, and one with acute infection.
Of 38 subjects randomized, 37 completed both phases of the
study, and one was discontinued during Phase 2 because of
hospitalization unrelated to the study device. All 38 ran-
domized subjects comprised the intent-to-treat population
and were included in all analyses. Six subjects had allowed
protocol deviations at study entry including fivewith baseline
bodymass index > 32 kg/m2 (32.2, 32.5, 35, 36.5, and 44.1 kg/
m2) (results were maintained if these subjects were excluded)
and one on a stable dose of lisinopril for 2 months instead of
3. Six subjects had allowed deviations during the study
(three with follow-up dates outside the visit window and
three with non-fasting clinic blood draws due to preceding
hypoglycemia). Table 1 shows baseline characteristics of the
38 subjects in the intent-to-treat population according to
randomized sequence group. Before entering the study,
subjects in both sequence groups had similar daily insulin
doses. During the study, insulin doses (mean – SE) remained
within 10% of baseline and were similar for bolus-patch
(total, basal, and mealtime, 60.4 – 4.5, 33.4 – 3.2, and
27.9 – 2.0 units/day, respectively) and pen/syringe (total,
basal, and mealtime, 65.3 – 5.4, 37.7 – 4.7, and 28.4 – 1.9
units/day, respectively).
Glycemic control and variability indices
Indices are presented as mean – SE. Figure 2 displays
MDBG at run-in and end point on the devices. The primary
end point of equivalence of MDBG (in mmol/L) using bolus-
patch (8.61 – 0.28) compared with pen/syringe (9.02 – 0.26)
was met as the 95% upper confidence interval (mmol/L) of
the treatment difference was within the upper equivalence
margin of 1.11 (95% confidence interval, - 0.97 to 0.16). For
the subgroup of type 1 subjects, MDBG was also equivalent
between bolus-patch (8.64 – 0.37) and pen/syringe
(9.14 – 0.30) (95% confidence interval, - 1.30 to 0.37). For
secondary end points, there was a nonsignificant trend to-
ward a lower MDBG by - 0.42 using bolus-patch (P = 0.098).
The SD (mmol/L) of the seven-point blood glucose values
was significantly (P = 0.004) lower using bolus-patch
(3.18 – 0.18) versus pen/syringe (3.63 – 0.17), as was the CV
(bolus-patch vs. pen/syringe, 37.2 – 1.7% vs. 40.3 – 1.7%;
P = 0.046). The M-value also trended lower (P = 0.097) using
bolus-patch (368.4 – 40.5) versus pen/syringe (428.3 – 38.2).
There was no difference in MAGE (in mmol/L) between de-
vices (bolus-patch vs. pen/syringe, 5.66 – 0.41 vs. 6.11 – 0.37;
P = 0.396). The mean of premeal blood glucose values) also
trended lower while using bolus-patch (bolus-patch vs. pen/
syringe, 8.14 – 0.29 vs. 8.77 – 0.34mmol/L; P = 0.066). The
mean of postmeal BG values was similar between de-
vices (bolus-patch vs. pen/syringe, 8.84 – 0.34 vs. 9.30 –
0.31mmol/L; P = 0.234). There were no differences between
devices for bedtime blood glucose values. HbA1c (bolus-
patch vs. pen/syringe, 7.6 – 0.1% vs. 7.6 – 0.1%; P = 0.944), 1,5-
anhydroglucitol (bolus-patch vs. pen/syringe, 5.4 – 0.6 vs.
5.2 – 0.6 lg/mL; P = 0.358), and fructosamine (bolus-patch
FIG. 1. Insulin bolus-patch (Finesse, Calibra Medical Inc.). (A) Bolus-patch size is 6· 3· 8mm. (B) Bolus-patch is wearable
for up to 3 days. (C) Mealtime insulin can be dosed through clothing. (D) Mealtime insulin is administered by actuating the
buttons on both sides of the bolus-patch.
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vs. pen/syringe, 325.8– 8.1 vs. 322.5– 9.4mmol/L; P = 0.116)
were similar between devices. Body weight during the
study was stable (bolus-patch vs. pen/syringe, 87.1 – 2.4 vs.
87.2 – 2.4 kg). Secondary end points were maintained for the
subgroup of type 1 subjects.
There was no significant interaction by sequence (carryover
effect) or period (Phase 1 vs. Phase 2) for any of the glycemic
control measures. Subgroup analyses showed no interactions
of MDBG (bolus-patch minus usual device) (mean; 95% con-
fidence interval) (in mmol/L) by treatments for pen (0.01;
Table 1. Baseline Characteristics of 38 Subjects in the Intent-to-Treat Population
(Subjects Who Were Randomized)
Sequence group
Pen/syringe to
bolus-patch (n = 19)
Bolus-patch to
pen/syringe (n = 19) All (n = 38)
Age (years) 44.9 (15.3) 49.8 (15.5) 47.3 (15.4)
Min, Max 23, 72 22, 75 22, 75
Gender [n (%)]
Female 5 (26.3%) 8 (42.1%) 13 (34.2%)
Male 14 (73.7%) 11 (57.9%) 25 (65.8%)
Race [n (%)]
Black 1 (5.3%) 1 (2.6%)
Hispanic/Latino 1 (5.3%) 3 (15.8%) 4 (10.5%)
White 17 (89.5%) 16 (84.2%) 33 (86.8%)
BMI (kg/m2) 28.2 (3.4) 29.7 (4.9) 29.0 (4.2)
Min, Max 21.0, 32.5 22.5, 44.1 21.0, 44.1
Type of diabetes [n (%)]
Type 1 14 (73.7%) 12 (63.2%) 26 (68.4%)
Type 2 5 (26.3%) 7 (36.8%) 12 (31.6%)
Usual device [n (%)]
Both (pen and syringe) 4 (21.1%) 2 (10.5%) 6 (15.8%)
Insulin pen 7 (36.8%) 8 (42.1%) 15 (39.5%)
Syringe 8 (42.1%) 9 (47.4%) 17 (44.7%)
Duration of diabetes (years) 20.6 (9.7) 21.8 (7.7) 21.2 (8.7)
Min, Max 4.5, 40.1 8.1, 36.3 4.5, 40.1
Basal insulin dose (units) 40.5 (43.5) 41.6 (30.3) 41.1 (37.0)
Min, Max 12.0, 200.0 13.0, 150.0 12.0, 200.0
Duration of using basal insulin 5.2 (2.9) 5.1 (4.5) 5.2 (3.8)
Lantus/Levemir (years)
Min, Max 1.5 10.2 0.7, 20.0 0.7, 20.0
Mealtime insulin dose (units) 31.0 (11.8) 33.7 (12.8) 32.3 (12.2)
Min, Max 20.0, 60.0 16.0, 60.0 16.0, 60.0
Duration of using mealtime insulin 6.2 (4.0) 4.4 (3.4) 5.3 (3.8)
Humalog/NovoLog (years)
Min, Max 0.6, 12.1 0.7, 13.5 0.6, 13.5
HbA1c (%) 8.2 (0.7) 8.0 (0.7) 8.1 (0.7)
Min, Max 7.1, 9.3 7.0, 9.5 7.0, 9.5
AST (U/L) 20.0 (6.4) 20.1 (6.9) 20.1 (6.6)
Min, Max 12.0, 39.0 10.0, 32.0 10.0, 39.0
ALT (U/L) 21.6 (9.9) 22.5 (12.6) 22.1 (11.2)
Min, Max 11.0, 48.0 7.0, 47.0 7.0, 48.0
Creatinine (lmol/L) 88.4 (26.5) 79.6 (17.7) 79.6 (26.5)
Min, Max 53.0, 176.8 53.0, 123.8 53.0, 176.8
Basal insulin [n (%)]
Lantus 17 (89.5%) 16 (84.2%) 33 (86.8%)
Levemir 2 (10.5%) 3 (15.8%) 5 (13.2%)
Mealtime insulin [n (%)]
Humalog 10 (52.6%) 11 (57.9%) 21 (55.3%)
NovoLog 9 (47.4%) 8 (42.1%) 17 (44.7%)
Data are mean– SD values. The insulin bolus-patch used was Finesse (Calibra Medical, Inc., Redwood City, CA). Humalog, Lantus,
Levemir, and NovoLog are products of Eli Lilly and Co. (Indianapolis, IN), Sanofi-Aventis (Bridgewater, NJ), Novo Nordisk
Pharmaceuticals Inc. (Princeton, NJ), and Novo Nordisk, respectively.
ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass index; HbA1c, glycated hemoglobin; Max, maximum;
Min, minimum.
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-0.03, 0.05) compared with syringe (0.04; - 0.00, 0.08) users,
by gender for females (0.45; - 0.39, 1.29) comparedwithmales
(0.30; - 0.22, 1.02), and by age for age < 65 years (0.02; - 0.01,
0.05) compared with age ‡ 65 years (0.03; - 0.03, 0.09).
Device satisfaction and quality of life
Subjects preferred bolus-patch over pen/syringe on five of
six IDSRQ subscales (Table 2). At study completion, 76% of
subjects wanted to switch from their pen/syringe to bolus-
patch (P = 0.001). Pen and syringe users equally preferred
bolus-patch over injection, as did subjects with type 1 or type
2 diabetes. The treatment order did not impact preference as
patients preferred bolus-patch whether they used it in Phase 1
or Phase 2.
Subjects scored significantly better on six of seven subscales
on DSQOLS while using bolus-patch versus pen/syringe
(Table 2). The QOL for subjects improved while using bolus-
patch for both pen and syringe users and for subjects with
type 1 or 2 diabetes.
FIG. 2. Mean daily blood glucose (in mmol/L) in 38 subjects (intent-to-treat population) by treatment sequence at baseline,
the 6-week crossover (end of Phase 1), and the 12-week completion (end of Phase 2). Data are mean – SE values. The mean
daily blood glucose was lower by - 0.42mmol/L using bolus-patch versus pen/syringe (P = 0.098). *Bolus-patch is Finesse
from Calibra Medical Inc.
Table 2. Summary of Results of Insulin Delivery System Rating Questionnaire and Diabetes Specific Quality
of Life Scale in 38 Subjects (Intent-to-Treat Population) by Treatment Device
Bolus-patch (n = 38) Pen/syringe (n = 37) Device difference P value
IDSRQ subscale
Satisfactiona 82.9 (14.5) 54.9 (17.5) 27.7 (22.7) < 0.001
Interfereb 14.5 (15.9) 25.0 (18.5) - 10.1 (23.1) 0.009
Helpinga 61.4 (18.7) 50.7 (13.7) 10.6 (22.7) 0.007
Worryb 36.6 (15.5) 41.8 (19.2) - 4.5 (12.7) 0.035
Feelingsa 64.5 (13.8) 61.9 (13.7) 2.1 (10.4) 0.205
Overall Satisfactionb 1.9 (0.7) 2.6 (0.6) - 0.6 (0.9) < 0.001
DSQOLS subscale
Treatment Goalsb 23.6 (11.0) 23.8 (9.8) 0.1 (6.4) 0.972
Treatment Satisfactionb 29.5 (13.5) 38.4 (10.0) - 8.7 (12.2) < 0.001
Physical Complaintsa 78.0 (16.7) 74.4 (15.3) 3.1 (8.3) 0.029
Emotional Burdens And Worriesa 65.3 (23.4) 58.8 (23.7) 5.7 (11.1) 0.003
Social Problemsa 85.0 (18.7) 81.3 (20.9) 3.3 (9.1) 0.032
Daily Functionsa 68.3 (16.9) 61.2 (16.8) 6.5 (11.7) 0.002
Diet Restrictionsa 70.9 (15.0) 65.0 (15.1) 5.5 (13.7) 0.017
Data are mean– standard deviation.
The answers on the Insulin Delivery System Rating Questionnaire (IDSRQ)14 and the Diabetes Specific Quality of Life Scale (DSQOLS)15
were scored on a scale of 0–100 to standardize as described in the original articles except for IDSRQ, Overall Satisfaction, which was on a scale
of 1–4.
aHigher score is better.
bLower score is better.
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Safety profile
Eighteen AEs were reported during the study: one at
baseline and 17 during the study. Eight AEs were reported
during bolus-patch use, and nine during pen/syringe use.
Eight of 38 subjects (21%) during bolus-patch use and eight of
37 subjects (22%) during pen/syringe use reported one or
more AEs. The frequencies of the most common AEs were
similar between treatments and included gastrointestinal
disorders, infections, musculoskeletal and skin discomfort,
and respiratory disorders. There were two serious AEs, both
unrelated to the study devices: one during bolus-patch use
(acute bronchitis) and one during pen/syringe use (acute
pancreatitis with subject withdrawal for prolonged hospital-
ization). There were no serious ADEs for bolus-patch or pen/
syringe. Insertion site reactions showed no differences be-
tween devices for irritation (erythema or papular reaction),
edema, or ecchymosis.
There were no severe hypoglycemia or hyperglycemia
episodes during the study. The incidence of non-severe bio-
chemical hypoglycemia was similar for bolus-patch versus
pen/syringe (34 of 38 subjects [89.5%] vs. 33 of 36 subjects
[91.7%]; P = 0.655). Non-severe biochemical hyperglycemia
incidence was also similar for bolus-patch versus pen/syringe
(37 of 38 subjects [97.4%] vs. 36 of 36 subjects [100%];
P = 1.000).
Discussion
This feasibility study reports the first clinical use of a
novel bolus-patch for patients prescribed a multiple daily
injection insulin regimen. While using the bolus-patch,
subjects had equivalent MDBG, less glycemic variability
(SD and CV), improved device satisfaction, and better QOL
compared with using their pen/syringe. Use of bolus-patch
resulted in a safety profile that was similar to that of pen/
syringe. All these findings suggest that the bolus-patch is
a suitable alternative to current injection devices (pen/
syringe) that deliver bolus insulin. Additionally, over a 3-
day period, the bolus-patch required one skin penetration
compared with nine skin penetrations with pen/syringe for
administering bolus insulin.
That SD and CV (but not M-value and MAGE) only were
significantly different with the bolus-patch may reflect the
modest sample size of the study as the power calculation of
the study was not based on glycemic variability. The study
was powered to test the equivalence of MDBG but not pow-
ered to assess differences in glycemic control indices; it found
no differences in HbA1c, 1,5-anhydroglucitol, and fructosa-
mine between treatment groups. Nor was it powered to show
device satisfaction by age, gender, or ethnicity. However, five
of seven people over age 65 years preferred bolus-patch to
injection.
Use of bolus-patch resulted in a safety profile that was
similar to that of pen/syringe. AEs were similar between
devices and were unrelated to the devices. Injection site re-
actions were not significantly different between devices and
did not result in any subject withdrawing from the study.
Incidence rates of non-severe biochemical hypoglycemia were
similar between devices. The easier access to insulin with
bolus-patch did not result in any severe hypoglycemia epi-
sodes. The similar incidence rates of non-severe biochemical
hyperglycemia between devices suggest that subjects were
able to easily use bolus-patch and had no problems with in-
sulin delivery via a subcutaneous cannula. A safety feature on
the bolus-patch alerts the patient if no insulin is delivered.
Other studies that compared pen versus syringe in adults
with type 1 or 2 diabetes have shown patient preference for
disposable pens but have not shown a change in glycemic
indices versus the syringe.16–19 The present study showed a
patient preference for bolus-patch over pen/syringe without
a difference in glycemic control indices. The pen offers the
convenience of having a prefilled insulin delivery device but
still requires multiple daily injections and does not offer the
ease of use and discreetness of the wearable bolus-patch. Al-
though not intended to replace traditional pumps, the bolus-
patch offers some of the pump advantages, including users
have bolus insulin with them all the time, can discreetly dose
bolus insulin in social situations, and only have to penetrate
the skin once every 3 days for bolus dosing [they still need to
give basal injection(s) daily]. The bolus-patch also has ad-
vantages over traditional pumps in that pumps are much
higher in cost20 and more complex to use.21 However, the
bolus-patch does not have the basal insulin infusion that
traditional pumps have.
This feasibility study has limitations. Mealtime carbohy-
drate intake was not available to assess appropriateness of
insulin dose during treatments. The limited days of diary re-
cordings did not show differences in bolus insulin usage be-
tween devices. The short duration of the study precludes
comments on longer-term outcomes.
In conclusion, bolus-patch offers the safety and efficacy of
insulin administration by pen/syringe without multiple daily
injections. Bolus-patch also allowed subjects greater ease in
delivering bolus insulin and improved their QOL. The results
of this study encourage larger and longer-term studies to
evaluate if using the bolus-patch allows patients to more
consistently cover meals and snacks as recommended by their
clinical team compared with pen/syringe.
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